<code id='A227AABE52'></code><style id='A227AABE52'></style>
    • <acronym id='A227AABE52'></acronym>
      <center id='A227AABE52'><center id='A227AABE52'><tfoot id='A227AABE52'></tfoot></center><abbr id='A227AABE52'><dir id='A227AABE52'><tfoot id='A227AABE52'></tfoot><noframes id='A227AABE52'>

    • <optgroup id='A227AABE52'><strike id='A227AABE52'><sup id='A227AABE52'></sup></strike><code id='A227AABE52'></code></optgroup>
        1. <b id='A227AABE52'><label id='A227AABE52'><select id='A227AABE52'><dt id='A227AABE52'><span id='A227AABE52'></span></dt></select></label></b><u id='A227AABE52'></u>
          <i id='A227AABE52'><strike id='A227AABE52'><tt id='A227AABE52'><pre id='A227AABE52'></pre></tt></strike></i>

          leisure time

          leisure time

          author:fashion    Page View:12
          Johnson & Johnson logo. -- health coverage from STAT.
          Chris O'Meara/AP

          Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

          Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

          advertisement

          In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Change Healthcare cyberattack outage could last weeks
          Change Healthcare cyberattack outage could last weeks

          AdobeTheoutagecausedbytheChangeHealthcarecyberattackcouldlastweeks,atopUnitedHealthexecutivesuggeste

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Pfizer highlights cancer drugs it thinks could reignite investor interest

          AscreenattheNewYorkStockExchangelastNovember.MichaelM.Santiago/GettyImagesPfizerspentmorethanfourhou